

#24

DOCKET NO.: ORT-1060 (PRI-0003)

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Alain T. Luxebourg, Michael R. Jackson

And Pre A. Peterson

Serial No.: 09/434,965

Filing Date: November 5, 1999

For: PURIFICATION OF ANTIGEN-SPECIFIC T CELLS


Confirmation No.: 4589

Group Art Unit: 1644

Examiner: A. M. DeCloux

DATE OF DEPOSIT: January 30, 2003

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE COMMISSIONER OF PATENTS AND TRADEMARKS, WASHINGTON, DC 20231.


TYPED NAME: Felicity E. Groth
REGISTRATION NO.: 47,042

Attention: Office of Petitions
Box DAC
Assistant Commissioner for Patents
Washington, DC 20231

Sir:

RECEIVED
FEB 10 2003
OFFICE OF PETITIONS

TRANSMITTAL LETTER TO OFFICIAL DRAFTSMAN

Please find enclosed 29 sheet(s) of formal drawings comprising Figures 1A, 1B, 1C, 1D, 2A, 2B, 2C, 2D, 2E, 2F, 3A, 3B, 3C, 3D, 3E, 3F, 3G, 3H, 4A, 4B, 4C, 4D, 4E, 4F, 5A, 5B, 5C, 5D, 5E, 6A, 6B, 6C, 6D, 7A, 7B, 7C, 7D, 8A, And 8B relating to the above-identified patent application.


This Letter, and the enclosed drawings, each bear the Serial No. (if assigned yet), Title, Inventor Name(s), Docket No. and name and telephone number of responsible attorney

DOCKET NO.: ORT-1060 (PRI-0003) - 2 -

PATENT

of the application on the front of the respective document. Please charge any comparison fees to our Deposit Account No. 23-3050.

Date: January 30, 2003



Felicity E. Groth
Registration No. 47,042

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2003 WW

1/29





FIG. 1A



2/29





FIG. 1B



3/29




FIG. 1C



4/29




FIG. 1D



5/29




FIG. 2A



6/29




FIG. 2B



7/29




FIG. 2C



8/29




FIG. 2D



9/29




FIG. 2E

10/29




FIG. 2F



11/29





FIG. 3A



12/29





FIG. 3B



13/29





FIG. 3C



14/29




FIG. 3D



15/29




FIG. 3E



16/29




FIG. 3F



17/29




FIG. 3G



18/29




FIG. 3H




FIG. 4A



4°C
Room Temperature
37°C




FIG. 4B




FIG. 4C




FIG. 4D





FIG. 4E



21/29




FIG. 4F



22/29




FIG. 5A



Docket No.: ORT-1060 (PRI-0003).
App No.: 09/434,965 Filed: 11/05/99
Title: Purification Of Antigen-Specific T-Cells
Inventors: Luxembourg, Et Al.
Attorney: DBE/JER/FEG Phone: (215) 568-3100
Sheet 23 of 29

23/29




FIG. 5B



Docket No.: ORT-1060 (PRI-0003)
App No.: 09/434,965 Filed: 11/05/99
Title: Purification Of Antigen-Specific T-Cells
Inventors: Luxembourg, Et Al.
Attorney: DBE/JER/FEG Phone: (215) 568-3100
Sheet 24 of 29

24/29





FIG. 5C



25/29




FIG. 5D



26/29




FIG. 5E



27/29
**Peptides Used For
Chromium Release Assay**

- ▲ OVA8
- VSV8
- No Peptide




FIG. 6A




FIG. 6B




FIG. 6C





FIG. 6D



28/29

Targets = RMA.S-L^d

LCMV Peptide NP118-126

○ MCMV Peptide pp89 168-176




FIG. 7A

Targets = BALB/c CL-7 (H-2^d)

● LCMV-infected Targets

○ Uninfected Targets




FIG. 7B

Targets = MC57 (H-2^b)

● LCMV-infected Targets

○ Uninfected Targets




FIG. 7C

Targets = YAC.1




FIG. 7D